A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT05859074
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MQ719 — BIOLOGICAL
    Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
  • Pembrolizumab — DRUG
    Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.

Study Details

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

Key Dates

Start date
May 4, 2023
Status verified
Dec 2025
Primary completion
May 4, 2028
Completion
May 4, 2028

Study Design

Enrollment
56 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation Group
    MQ710 The dose levels will be escalated following a standard 3+3 dose escalation scheme.
  • Experimental: Dose Expansion Group
    MQ710 + pembrolizumab Approximately 8 patients will be recruited into the dose expansion group for monotherapy dosing of MQ710. Approximately 12 patients will be recruited for dosing at the MTD/maximally administered dose established in combination with pembrolizumab.

Primary Outcome Measure

Safety of MQ710 by review of AEs and SAEs [ Time Frame: Up to 2 years ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking RidgeNew Jersey07920
Lara Dunn, MD
646-608-3787
Memorial Sloan Kettering Monmouth (Limited protocol activities)MiddletownNew Jersey07748
Lara Dunn, MD
646-608-3787
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew Jersey07645
Lara Dunn, MD
646-608-3787
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)CommackNew York11725-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew York10604-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Lara Dunn, MD
646-608-3787
Memorial Sloan Kettering Nassau (Limited Protocol Activities)UniondaleNew York11553
Lara Dunn, MD
646-608-3787

Find similar trials in Basking Ridge, NJ

By condition
Skin cancerHead and neck cancerMelanoma
By specialty
OncologySkin cancerDermatologyENT
By research site
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited protocol activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies